In a report released today, Yigal Nochomovitz from Citigroup maintained a Hold rating on Zymeworks Inc (NYSE: ZYME), with a price target of $19. The company’s shares closed yesterday at $16.56.
According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of 13.3% and a 52.3% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Ovid Therapeutics Inc, Puma Biotechnology, and Portola Pharma.
Zymeworks Inc has an analyst consensus of Moderate Buy, with a price target consensus of $23.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29 and a one-year low of $6.25. Currently, Zymeworks Inc has an average volume of 157.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that can two non-overlapping epitopes.
